Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Sponsor: National Cancer Institute (NCI)
A PHASE2 clinical study on Neurofibroma, Plexiform and Neurofibromatosis 1, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — May 2018 [monthly]
Completed PHASE2
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Bethesda, United States, Birmingham, United States, Boston, United States, Chicago, United States, Cleveland, United States, Houston, United States, New York, United States, Philadelphia, United States, Pittsburgh, United States and 5 more location s